<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35314144</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7905</ISSN><JournalIssue CitedMedium="Internet"><Volume>504</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of immunological methods</Title><ISOAbbreviation>J Immunol Methods</ISOAbbreviation></Journal><ArticleTitle>VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.</ArticleTitle><Pagination><StartPage>113259</StartPage><MedlinePgn>113259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jim.2022.113259</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-1759(22)00046-1</ELocationID><Abstract><AbstractText>Next generation poliovirus vaccines are critical to reaching global poliovirus eradication goals. Recent efforts have focused on creating inactivated vaccines using attenuated Sabin strains that maintain patient safety benefits and immunogenicity of conventional inactivated vaccines while increasing manufacturing safety and lowering production costs, and on developing novel oral vaccines using modified Sabin strains that provide critical mucosal immunity but are further attenuated to minimize risk of reversion to neurovirulence. In addition, there is a push to improve the analytical tools for poliovirus vaccine characterization. Conventional and Sabin inactivated poliovirus vaccines typically rely on standard plate-based ELISA as in vitro D-antigen potency assays in combination with WHO international standards as calibrants. While widely utilized, the current D-antigen ELISA assays have a long time to result (up to 72 h), can suffer from lab-to-lab inconsistency due to non-standardized protocols and reagents, and are inherently singleplex. For D-antigen quantitation, we have developed the VaxArray Polio Assay Kit, a multiplexed, microarray-based immunoassay that uses poliovirus-specific human monoclonal antibodies currently under consideration as standardized reagents for characterizing inactivated Sabin and Salk vaccines. The VaxArray assay can simultaneously quantify all 3 poliovirus serotypes with a time to result of less than 3 h. Here we demonstrate that the assay has limits of quantification suitable for both bioprocess samples and final vaccines, excellent reproducibility and precision, and improved accuracy over an analogous plate-based ELISA. The assay is suitable for adjuvanted combination vaccines, as common vaccine additives and crude matrices do not interfere with quantification, and is intended as a high throughput, standardized quantitation tool to aid inactivated poliovirus vaccine manufacturers in streamlining vaccine development and manufacturing, aiding the global polio eradication effort.</AbstractText><CopyrightInformation>Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Erica D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA. Electronic address: dawson@indevr.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Amber W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Tianjing</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Keely N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Rachel Y</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahid</LastName><ForeName>Rahnuma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PATH, 2201 Westlake Avenue, Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahmood</LastName><ForeName>Kutub</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>PATH, 2201 Westlake Avenue, Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlen</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Immunol Methods</MedlineTA><NlmUniqueID>1305440</NlmUniqueID><ISSNLinking>0022-1759</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">D-antigen ELISA</Keyword><Keyword MajorTopicYN="N">Immunoassay</Keyword><Keyword MajorTopicYN="N">Microarray</Keyword><Keyword MajorTopicYN="N">Poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Potency</Keyword><Keyword MajorTopicYN="N">VaxArray</Keyword></KeywordList><CoiStatement>E. Dawson and K. Rowlen are stockholders of InDevR, Inc. E. Dawson, K. Rowlen, J. Johnson, Jr., A. Taylor, T. Hu, C. McCormick, K. Thomas, R Gao are employed by InDevR, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35314144</ArticleId><ArticleId IdType="pmc">PMC9072286</ArticleId><ArticleId IdType="doi">10.1016/j.jim.2022.113259</ArticleId><ArticleId IdType="pii">S0022-1759(22)00046-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bandyopadhyay A.S., Macklin G.R. Final frontiers of the polio eradication endgame. Curr. Opin. Infect. Dis. 2020;33(5):404–410.</Citation><ArticleIdList><ArticleId IdType="pubmed">32773500</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawt L., Atkinson E., Tedcastle A., Pegg E., the sIPV Study Group, Minor P., Cooper G., Rigsby P., Martin J. differences in antigenic structure of inactivated polio vaccines made from Sabin live-attenuated and wild-type poliovirus strains: Impact on Vaccine Potency Assays. J. Infect. Dis. 2020;221:545–552.</Citation><ArticleIdList><ArticleId IdType="pubmed">30788503</ArticleId></ArticleIdList></Reference><Reference><Citation>Daptacel . Sanofi Pasteur Limited; Toronto, Canada: 2021. package insert. R10–0916 USA.</Citation></Reference><Reference><Citation>Dyer O. Polio: WHO declares type 3 poliovirus eradicated after 31 year campaign. BMJ. 2019;367:I6201.</Citation><ArticleIdList><ArticleId IdType="pubmed">31649018</ArticleId></ArticleIdList></Reference><Reference><Citation>Engerix B. GlaxoSmithKline Biologicals; Rixensart, Belgium: 2021. package insert.</Citation></Reference><Reference><Citation>IPOL . Sanofi Pasteur Inc; Swiftwater, PA: 2021. package insert. v 0.1 969640.</Citation></Reference><Reference><Citation>Kouiavskaia D., Puligedda R.D., Dessain S.K., Chumakov K. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines. J. Virol. Methods. 2020;276</Citation><ArticleIdList><ArticleId IdType="pubmed">31765719</ArticleId></ArticleIdList></Reference><Reference><Citation>List of Prequalified Vaccines WHO. 2021. https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines (accessed July 20, 2021)</Citation></Reference><Reference><Citation>Maughan C.N., Preston S.G., Williams G.R. Particulate inorganic adjuvants: recent developments and future outlooks. J. Pharm. Pharmacol. 2014;67:426–449.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496339</ArticleId></ArticleIdList></Reference><Reference><Citation>McAdams D., Lakatos K., Estrada M., Chen D., Plikaytis B., Sitrin R., White J.A. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant. J. Immunol. Methods. 2021;494</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8208242</ArticleId><ArticleId IdType="pubmed">33857473</ArticleId></ArticleIdList></Reference><Reference><Citation>Modlin J.F., Chumakov K. Sabin strain inactivated polio vaccine for the polio endgame. J. Infect. Dis. 2020;221:504–505.</Citation><ArticleIdList><ArticleId IdType="pubmed">30788498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudholkar S.S. ProQuest Information and Learning Company; 2001. Relationship Between the Degree of Antigen Adsorption in the Vaccine or in Interstitial Fluid and the Ensuing Immune Response. (Publication No. 3075704) [Doctoral dissertation, Purdue University]</Citation></Reference><Reference><Citation>Okayasu H., Sein C., Hamidi A., Bakker W.A.M., Sutter R.W. Development of inactivated poliovirus vaccine from Sabin strains: A progress report. Biologicals. 2016;44(6):581–587.</Citation><ArticleIdList><ArticleId IdType="pubmed">27720268</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch M.A. Ending use of oral poliovirus vaccine – A difficult move in the polio endgame. N. Engl. J. Med. 2018;379(9):801–803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083018</ArticleId><ArticleId IdType="pubmed">30157390</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediarix . GlaxoSmithKline Biologicals; Rixensart, Belgium: 2019. Package Insert.</Citation></Reference><Reference><Citation>Pentacel . Sanofi Pasteur Limited; Toronto, Canada: 2021. package insert. R9–0820 USA.</Citation></Reference><Reference><Citation>Rinella J.V., Jr., White J.L., Hem S.L. Effect of pH on the elution of model antigens from aluminum-containing adjuvants. J. Colloid Interface Sci. 1998;205:161–165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710509</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinella J.V., Jr., Workman R.F., Hermodson M.A., White J.L., Hem S.L. Elutability of proteins from aluminum-containing vaccine adjuvants by treatment with surfactants. J. Colloid Interface Sci. 1998;197:48–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466843</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi O., Aruta M.G., Acquaviva A., Mancini F., Micoli F., Necchi F. Characterization of competitive ELISA and Formulated Alhydrogel competitive ELISA (FAcE) for direct quantification of active ingredients in GMMA-based vaccines. Methods Protoc. 2020;3:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7563494</ArticleId><ArticleId IdType="pubmed">32878036</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeber S., White J.L., Hem S.L. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J. Parenter. Sci. Technol. 1991;45:156–159.</Citation><ArticleIdList><ArticleId IdType="pubmed">1886045</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomassen Y.E., Bakker W.A.M. sIPV process development for costs reduction. Vaccine. 2015;33:4307–4312.</Citation><ArticleIdList><ArticleId IdType="pubmed">25858858</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomassen Y.E., Van’t Oever A.G., Van Oijen M.G.C.T., Wijffels R.H., van der Pol L.A., Bakker W.A.M. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS One. 2013;8(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861478</ArticleId><ArticleId IdType="pubmed">24349497</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashishtha V.M., Kamath S. A brief history of vaccines against polio. Indian Pediatr. 2016;53:S20–S27.</Citation><ArticleIdList><ArticleId IdType="pubmed">27771635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee P.T.I., Poh C.L. The final stage of developing genetically modified inactivated Sabin vaccine for the eradication of poliovirus, Austin. J. Microbiol. 2015;1(2):id1009.</Citation></Reference><Reference><Citation>Zhu D., Saul A., Huang S., Martin L.B., Miller L.H., Rausch K.M. Use of O-phthalaldehyde assay to determine protein contents of alhydrogel-based vaccines. Vaccine. 2009;27:6054–6059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753737</ArticleId><ArticleId IdType="pubmed">19660590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D., Huang S., McClellan H., Dai W., Syed N.R., Gebregeorgis E., Mullen G.E.D., Long C., Martin L.B., Narum D., Duffy P., Miller L.H., Saul A. Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine. 2012;30:189–194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246088</ArticleId><ArticleId IdType="pubmed">22107848</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>